statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Announcing OBA clinical development program by Biophytis with BIO101 (20-hydroxyecdysone) for obesity treatment. Phase 2 study expected mid-2024, with efficacy results anticipated in 2025.
read more...

Why Is Penny Stock Biophytis Trading Higher On Tuesday?

Gagnants
Le titre Acrivon Therapeutics (NASDAQ:ACRV) a mont mardi de 75,12% 10,35 dollars lors de la session pre-market.
Le titre Biophytis (NASDAQ:BPTS) a augment de 40,48% 0,45 dollars.
Le...

12 titres de soins de sant  en mouvement lors de la pr -ouverture le 09/04/2024

Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today's pre-market trading after reporting FY23 results.
read more...

Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket

All resolutions presented by the Company have been adoptedPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 4, 2024 / Biophytis SA (NASDAQ:BPTS),(Euronext Growth Paris:ALBPS), ('Biophytis' or the...

Results of the Combined General Meeting on April 2, 2024

Biophytis S.A. (NASDAQ:BPTS - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 42,900 shares, a...

Short Interest in Biophytis S.A. (NASDAQ:BPTS) Increases By 44.4%

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novartis AG (CH:NOVN Research Report) and Biophytis SA...

Analysts Offer Insights on Healthcare Companies: Novartis AG (NOVN) and Biophytis SA (Frankfurt: DE:6XB)

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 22, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris:ALBPS), ('Biophytis' or the 'Company'), a clinical-stage biotechnology company...

Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia

Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 27, 2006 and is headquartered in Paris, France.

Volume	18,549.00
52-Wk High	$168.80
52-Wk Low	$8.05

BPTS Biophytis SA ADR

About

Feed

News

Fundamentals